

Human Intelligence Enhanced by Artificial Intelligence

A REVOLUTION IN STRUCTURAL HEART IDENTIFICATION AND MANAGEMENT

CardioCare


Quality Optimization Platform

The CardioCare platform is the leading solution in structural heart patient care, partnering with over 50 programs across the US to reduce variability in diagnoses and ensure patients receive timely treatment.

The CardioCare platform automatically identifies and prioritizes hospital systems' entire structural heart patient population, allowing physicians to provide care to the most at-risk patients now and in the future.

The CardioCare platform helps hospital systems address real-world challenges in structural heart patient care, helping physicians:

1. Reduce Mortality
2. Improve Guideline-Directed Therapy
3. Standardize Quality



The CardioCare platform helps physicians improve outcomes and guideline-directed therapy for structural heart patients.¹



Aortic Stenosis

↑ 45%



Mitral Regurgitation

↑ 54%



Tricuspid Regurgitation

↑ 46%

Why the CardioCare platform?



BIG DATA:

Leveraging AI from millions of records to help you understand your hospital's entire structural heart patient population



INSIGHTS ON DEMAND:

Prioritizing care for patients eligible for life saving treatment



PREDICTIVE ALGORITHMS:

Helping physicians identify patients with a higher likelihood of having undiagnosed severe disease

LOW GDMT RATES FOR HFrEF PATIENTS² DESPITE PROVEN BENEFITS³

2.4% of HFrEF patients on GDMT

70% improvement in 3-year survival⁴

70% reduction in 30-day heart failure related readmissions⁴

¹Analysis represents median growth from 8 CardioCare sites with baseline data one year after implementing the CardioCare platform.

²Data on file. Early data representing 5 heart programs managing more than 50,000 HFrEF patients. Heart failure with a reduced ejection fraction is defined as (HFrEF) and guideline-directed medical therapy (GDMT) is defined by patients being prescribed all 4 medications to treat heart failure. ³Maddox et al. (JACC 2021) <https://doi.org/10.1016/j.jacc.2020.11.022> Page 777, Section 5.1

⁴Data on file. Observed in patients prescribed all 4 guideline-directed medications compared to those with 0 guideline-directed medications.

For more information, please visit egnitehealth.com/solutions

@egnitehealth [linkedin.com/company/egnite-health/](https://www.linkedin.com/company/egnite-health/)

The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, or prevention of structural heart diseases.

©2022 egnite, Inc. All Rights Reserved. egnite, egnite Inc., the spark logo, CardioCare, and the heart logo are trademarks of egnite, Inc or its affiliates. All other trademarks are property of their respective owners.

PP-US-002 v4.0

